Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3938 studies found for:    novartis
Show Display Options
RSS Create an RSS feed from your search for:
novartis
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative
Conditions: Cardiovascular Disease;   Diabetes Type II;   Breast Cancer;   Asthma
Intervention: Other: Novartis Access
2 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
Conditions: Meningococcal Infections;   Meningococcal Meningitis
Interventions: Biological: MenACWY CRM;   Biological: Meningococcal ACWY Conjugate vaccine
3 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults
Conditions: Meningococcal Meningitis;   Meningococcal Infections
Interventions: Biological: Meningococcal ACWY Polysaccharide Vaccine;   Biological: MenACWY CRM (19 to 55 years);   Biological: Meningococcal ACWY Conjugate Vaccine;   Biological: Novartis MenACWY Vaccine (56 to 65 Years)
4 Unknown  Pilot Study of the Effectiveness of Probiotics and Lactitol for the Decolonization of OXA-48 (Carbapenemase) Producing Klebsiella Pneumoniae Among Rectal Carriers
Condition: Bacterial Colonization
Interventions: Drug: Lactitol;   Drug: Lactobacillus
5 Recruiting Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Condition: Neoplasms
Interventions: Drug: Everolimus;   Drug: Sandostatin LAR Depot
6 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents
Conditions: Meningococcal Meningitis;   Human Papillomavirus Infection;   Pertussis;   Tetanus
Interventions: Biological: Novartis Meningococcal ACWY Conjugate Vaccine;   Biological: Tdap Vaccine
7 Completed
Has Results
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
Condition: Meningococcal Infections
Interventions: Biological: MenACWY-CRM;   Biological: Licensed meningococcal ACWY vaccine
8 Completed Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.
Condition: Neoplasms
Intervention: Drug: Everolimus
9 Active, not recruiting Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: nilotinib
10 Completed Phase Ⅰ Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet
Condition: Healthy
Intervention: Drug: CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg
11 Completed Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg
Condition: Healthy
Interventions: Drug: CJ Amlodipine/Valsartan 10/160mg;   Drug: Novartis Exforge 10/160mg
12 Completed
Has Results
Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: MenC-CRM LIQ;   Biological: MenC-CRM ROS;   Biological: MenC-CRM EMV
13 Recruiting Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Conditions: Cushing's Disease;   Acromegaly;   Neuroendocrine Tumors;   Pituitary Tumors;   Ectopic ACTH Secreting (EAS) Tumors;   Dumping Syndrome;   Prostate Cancer;   Melanoma Negative for bRAF;   Melanoma Negative for nRAS
Intervention: Drug: Pasireotide
14 Completed
Has Results
Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.
Condition: Meningococcal Disease
Interventions: Biological: Meningococcal B Recombinant vaccine rMenB+OMV NZ;   Biological: Placebo;   Biological: Meningococcal ACWY-CRM conjugate vaccine
15 Completed Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study
Condition: Influenza
Intervention: Other: Non-intervention observational study
16 Active, not recruiting Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.
Condition: Meningococcal Disease
Interventions: Biological: Meningoccal B recombinant vaccine together with routine vaccines: DTaP-IPV-Hib, HepB, PCV (2-4-6 months of age) and MMRV (12 months of age);   Biological: Routine vaccines: DTaP-IPV-Hib, HepB, PCV (2-4-6 months of age) and MMRV (12 months of age)
17 Completed
Has Results
B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: MenACWY-CRM;   Biological: DTaP-Hib-IPV;   Biological: PCV;   Biological: MMR;   Biological: Hib
18 Completed
Has Results
Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults
Condition: Meningococcal Disease
Interventions: Biological: Men ACWY CRM;   Biological: 4CMenB
19 Completed
Has Results
Novartis Vaccine and Diagnostics Carriage Trial
Condition: N. Meningitidis Carriage
Interventions: Biological: Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ);   Biological: MenACWY-CRM conjugate vaccine;   Biological: Japanese Encephalitis vaccine
20 Active, not recruiting Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Condition: GIST and CML
Intervention: Drug: AMN107

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.